Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
Eur J Neurol. 2024 Dec;31(12):e16453. doi: 10.1111/ene.16453. Epub 2024 Aug 23.
The impact of bridging thrombolysis prior to endovascular thrombectomy (EVT) compared to EVT alone on intracerebral haemorrhage (ICH), subarachnoid haemorrhage (SAH), and death in anticoagulated atrial fibrillation (AF) patients with acute ischaemic stroke (AIS) is not well defined.
A retrospective study was conducted using data from a federated research network (TriNetX) including 114 health care organisations in the United States. Anticoagulated AF patients with AIS who received either bridging thrombolysis (BT) or EVT alone from September 2018 to November 2023 were included. Following propensity score matching, Cox regression analyses examined the risk of ICH, SAH, and death within 30 and 90 days, comparing anticoagulated AF patients receiving BT versus EVT only.
A total of 3156 patients with AIS were treated with BT or EVT alone. Following 1:1 propensity score matching, the cohort included 766 patients in each group. ICH occurred within 30 and 90 days in 6.9% and 8.0% in the BT group compared with 7.4% and 7.7% in the EVT-only group (hazard ratios [HR] = 0.92, 95% confidence interval [CI] = 0.63-1.33 and HR = 1.01, 95% CI = 0.71-1.45, respectively). SAH occurred within 30 and 90 days in 4.2% and 4.4% of patients in the BT compared to 3.0% and 3.4% in the EVT-only group (HR = 1.38, 95% CI = 0.81-2.38 and HR = 1.29, 95% CI = 0.77-2.14, respectively). Death occurred within 30 and 90 days in 17.8% and 19.8% of patients in the BT compared to 22.2% and 27.3% in the EVT-only group (HR = 0.77, 95% CI = 0.62-0.97 and HR = 0.65, 95% CI = 0.56-0.86, respectively).
In anticoagulated AF patients with AIS, BT was associated with a significantly lower risk of death, with no difference in ICH or SAH risk within 30 and 90 days compared to EVT only.
在接受抗凝治疗的心房颤动(AF)合并急性缺血性脑卒中(AIS)患者中,与单独血管内血栓切除术(EVT)相比,桥接溶栓(BT)对颅内出血(ICH)、蛛网膜下腔出血(SAH)和死亡的影响尚不清楚。
使用来自美国 114 个医疗保健机构的联邦研究网络(TriNetX)的数据进行回顾性研究。纳入 2018 年 9 月至 2023 年 11 月期间接受 BT 或单独 EVT 的接受抗凝治疗的 AF 合并 AIS 患者。在进行倾向评分匹配后,Cox 回归分析比较了接受 BT 与仅接受 EVT 的抗凝 AF 患者在 30 天和 90 天内发生 ICH、SAH 和死亡的风险。
共有 3156 例 AIS 患者接受 BT 或单独 EVT 治疗。在进行 1:1 倾向评分匹配后,每组纳入 766 例患者。BT 组 30 天和 90 天内 ICH 的发生率分别为 6.9%和 8.0%,而 EVT 组分别为 7.4%和 7.7%(风险比[HR] = 0.92,95%置信区间[CI] = 0.63-1.33 和 HR = 1.01,95%CI = 0.71-1.45)。BT 组 30 天和 90 天内 SAH 的发生率分别为 4.2%和 4.4%,而 EVT 组分别为 3.0%和 3.4%(HR = 1.38,95%CI = 0.81-2.38 和 HR = 1.29,95%CI = 0.77-2.14)。BT 组 30 天和 90 天内死亡的发生率分别为 17.8%和 19.8%,而 EVT 组分别为 22.2%和 27.3%(HR = 0.77,95%CI = 0.62-0.97 和 HR = 0.65,95%CI = 0.56-0.86)。
在接受抗凝治疗的 AF 合并 AIS 患者中,与单独 EVT 相比,BT 显著降低了死亡风险,而在 30 天和 90 天内 ICH 或 SAH 风险无差异。